Anti-angiogenic Ophthalmic Agents Market-Global Industry Analysis and Forecast (2023-2029)


Anti-angiogenic Ophthalmic Agents Market is expected to reach US$ 4.94 Bn. at a CAGR of 3.89% during the forecast period 2029.

Anti-angiogenic Ophthalmic Agents Market: Overview

The Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.Anti-angiogenic Ophthalmic Agents MarketTo Know About The Research Methodology :- Request Free Sample Report

Anti-angiogenic Ophthalmic Agents Market: Dynamics

Increasing prevalence of Ocular diseases is the key driving factor for the market growth.

Diabetic retinopathy remains one of the greatest challenges for healthcare system worldwide despite the fact that the incidence of visual acuity impairment in diabetic population has decreased due to examination quality improvement and dynamic observation of patients. According to the World Health Organization, a significant increase worldwide in number of patients with Diabetes Mellitus, is expected to reach 629 million by the year 2045. Along with this, rising prevalence of age-related macular degeneration (AMD), which is the leading cause of severe vision loss among geriatric population in many western countries is also bolstering the market growth. Many treatment options are available to treat the ocular diseases. The Laser Coagulation of the Retina (LCR) is used to treat diabetic retinal lesions. However, despite the proven efficacy of LCR some patients continue to lose their vision despite treatment. This may be due to both the complications of laser treatment (development of serpiginous atrophy and subretinal fibrosis) and resistance to its effects. This factor may restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.

Segment Analysis

By Indication Type, Macular Edema segment is expected to dominate the market.

Macular edema is the build-up of fluid in the macula, an area in the center of the retina. The retina is the light-sensitive tissue at the back of the eye and the macula is the part of the retina responsible for sharp, straight-ahead vision. Fluid buildup causes the macula to swell and thicken, which distorts vision. The current standard of care for macular edema is intravitreal injection or anti-VEGF injection. A recent NEI-supported clinical trial that directly compared the effectiveness of the three drugs for DME found that the drugs performed similarly for patients with mild vision problems. However, Eylea performed better for those with more serious vision loss. The global prevalence of Diabetic Macular Edema (DME) among individuals with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus varies by geographic region, with rates as low as 11.4% in European countries to as high as 45.3% in North American countries.

Regional Insights

North America accounted for largest market share in the year 2022, followed by Europe.

Increasing prevalence of eye related disorders like AMD, cataract, glaucoma, diabetic retinopathy, diabetic macular edema and dry eye disorders in the region and high availability of commercialized Anti-angiogenic Ophthalmic Agents are some of the driving factors for market in the region. Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among people aged 65 years and over in the United States and many western countries. For instance, in 2021, Bausch + Lomb launched Ocuvite Eye Performance vitamin supplements in the U.S. in order to meet the increasing needs of U.S. consumers. Besides this, Europe held the second largest share owing to increasing prevalence of myopic choroidal neovascularization in the region.

Asia Pacific is expected to witness fastest growth.

Increasing prevalence of diabetes and other eye related disorders in Asian countries with rising geriatric population pool who are more susceptible in acquiring these vision impairments will contribute to the market growth.

The report also helps in understanding Global Anti-angiogenic Ophthalmic Agents Market dynamics, structure by analyzing the market segments and project the Global Anti-angiogenic Ophthalmic Agents Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-angiogenic Ophthalmic Agents Market make the report investor’s guide.

Anti-angiogenic Ophthalmic Agents Market Scope: Inquire before buying






Anti-angiogenic Ophthalmic Agents Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 3.78 Bn.




Forecast Period 2023 to 2029 CAGR:
3.89%
Market Size in 2029:
US $ 4.94 Bn.




 Segments Covered:
by Indication Type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration




by Distribution Channel
Retail Pharmacies
Online pharmacies
Hospital pharmacies






Anti-angiogenic Ophthalmic Agents Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Anti-angiogenic Ophthalmic Agents Market Key Players

1. Gilead Sciences, Inc.
2. Eyetech Inc.
3. Becton, Dickinson and Company
4. Regeneron Pharmaceuticals, Inc.
5. Genentech, Inc.
6. Novartis AG
7. Allergan plc
8. Bayer AG
9. Santen Pharmaceutical Co., Ltd.
10.Shanghai Pharmaceuticals
11.Johnson & Johnson
12.Pfizer
13.Sun Pharma
14.Otsuka Pharmaceutical Co. Ltd
15.Daiichi Sankyo
16.ERC Labs
17.Medicom Health care
18.Implandata ophthalmic products GmbH
19.The Geuder Group, MORCHER GmbH
20.Novamedika

Frequently Asked Questions:

1. Which region has the largest share in Global Anti-angiogenic Ophthalmic Agents Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Anti-angiogenic Ophthalmic Agents Market?
Ans: The Global Anti-angiogenic Ophthalmic Agents Market is growing at a CAGR of 3.89% during forecasting period 2023-2029.

3. What is scope of the Global Anti-angiogenic Ophthalmic Agents Market report?
Ans: Global Anti-angiogenic Ophthalmic Agents Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Anti-angiogenic Ophthalmic Agents Market?
Ans: The important key players in the Global Anti-angiogenic Ophthalmic Agents Market are – Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG, Santen Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals, Johnson & Johnson, Pfizer, Sun Pharma, Otsuka Pharmaceutical Co. Ltd, Daiichi Sankyo, ERC Labs, and Medicom Health care.

5. What is the study period of this Market?
Ans: The Global Anti-angiogenic Ophthalmic Agents Market is studied from 2022 to 2029. 





Global Anti-angiogenic Ophthalmic Agents Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Anti-angiogenic Ophthalmic Agents Market Size, By Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Anti-angiogenic Ophthalmic Agents Market Analysis and Forecast
6.1. Anti-angiogenic Ophthalmic Agents Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Anti-angiogenic Ophthalmic Agents Market Analysis and Forecast, By Indication Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type
7.4. Anti-angiogenic Ophthalmic Agents Market Size (US$ Mn) Forecast, By Indication Type
7.5. Anti-angiogenic Ophthalmic Agents Market Analysis, By Indication Type
7.6. Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis, By Indication Type

8. Global Anti-angiogenic Ophthalmic Agents Market Analysis and Forecast, By Distribution Channel
8.1. Introduction and Definition
8.2. Key Findings
8.3. Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel
8.4. Anti-angiogenic Ophthalmic Agents Market Size (US$ Mn) Forecast, By Distribution Channel
8.5. Anti-angiogenic Ophthalmic Agents Market Analysis, By Distribution Channel
8.6. Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis, By Distribution Channel

9. Global Anti-angiogenic Ophthalmic Agents Market Analysis, By Region
9.1. Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Region
9.2. Anti-angiogenic Ophthalmic Agents Market Size (US$ Mn) Forecast, By Region
9.3. Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis, By Region

10. North America Anti-angiogenic Ophthalmic Agents Market Analysis
10.1. Key Findings
10.2. North America Anti-angiogenic Ophthalmic Agents Market Overview
10.3. North America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type
10.4. North America Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
10.4.1. Myopic Choroidal Neovascularization
10.4.2. Macular Edema
10.4.3. Diabetic Retinopathy
10.4.4. Macular Degeneration
10.5. North America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel
10.6. North America Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
10.6.1. Retail Pharmacies
10.6.2. Online pharmacies
10.6.3. Hospital pharmacies
10.7. North America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country
10.8. North America Anti-angiogenic Ophthalmic Agents Market Forecast, By Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America Anti-angiogenic Ophthalmic Agents Market Analysis, By Country
10.10. U.S. Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
10.10.1. Myopic Choroidal Neovascularization
10.10.2. Macular Edema
10.10.3. Diabetic Retinopathy
10.10.4. Macular Degeneration
10.11. U.S. Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
10.11.1. Retail Pharmacies
10.11.2. Online pharmacies
10.11.3. Hospital pharmacies
10.12. Canada Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
10.12.1. Myopic Choroidal Neovascularization
10.12.2. Macular Edema
10.12.3. Diabetic Retinopathy
10.12.4. Macular Degeneration
10.13. Canada Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
10.13.1. Retail Pharmacies
10.13.2. Online pharmacies
10.13.3. Hospital pharmacies
10.14. Mexico Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
10.14.1. Myopic Choroidal Neovascularization
10.14.2. Macular Edema
10.14.3. Diabetic Retinopathy
10.14.4. Macular Degeneration
10.15. Mexico Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
10.15.1. Retail Pharmacies
10.15.2. Online pharmacies
10.15.3. Hospital pharmacies
10.16. North America Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis
10.16.1. By Indication Type
10.16.2. By Distribution Channel
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments

11. Europe Anti-angiogenic Ophthalmic Agents Market Analysis
11.1. Key Findings
11.2. Europe Anti-angiogenic Ophthalmic Agents Market Overview
11.3. Europe Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type
11.4. Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.4.1. Myopic Choroidal Neovascularization
11.4.2. Macular Edema
11.4.3. Diabetic Retinopathy
11.4.4. Macular Degeneration
11.5. Europe Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel
11.6. Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.6.1. Retail Pharmacies
11.6.2. Online pharmacies
11.6.3. Hospital pharmacies
11.7. Europe Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country
11.8. Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Sweden
11.8.7. CIS countries
11.8.8. Rest of Europe
11.9. Germany Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.9.1. Myopic Choroidal Neovascularization
11.9.2. Macular Edema
11.9.3. Diabetic Retinopathy
11.9.4. Macular Degeneration
11.10. Germany Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.10.1. Retail Pharmacies
11.10.2. Online pharmacies
11.10.3. Hospital pharmacies
11.11. U.K. Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.11.1. Myopic Choroidal Neovascularization
11.11.2. Macular Edema
11.11.3. Diabetic Retinopathy
11.11.4. Macular Degeneration
11.12. U.K. Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.12.1. Retail Pharmacies
11.12.2. Online pharmacies
11.12.3. Hospital pharmacies
11.13. France Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.13.1. Myopic Choroidal Neovascularization
11.13.2. Macular Edema
11.13.3. Diabetic Retinopathy
11.13.4. Macular Degeneration
11.14. France Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.14.1. Retail Pharmacies
11.14.2. Online pharmacies
11.14.3. Hospital pharmacies
11.15. Italy Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.15.1. Myopic Choroidal Neovascularization
11.15.2. Macular Edema
11.15.3. Diabetic Retinopathy
11.15.4. Macular Degeneration
11.16. Italy Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.16.1. Retail Pharmacies
11.16.2. Online pharmacies
11.16.3. Hospital pharmacies
11.17. Spain Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.17.1. Myopic Choroidal Neovascularization
11.17.2. Macular Edema
11.17.3. Diabetic Retinopathy
11.17.4. Macular Degeneration
11.18. Spain Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.18.1. Retail Pharmacies
11.18.2. Online pharmacies
11.18.3. Hospital pharmacies
11.19. Sweden Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.19.1. Myopic Choroidal Neovascularization
11.19.2. Macular Edema
11.19.3. Diabetic Retinopathy
11.19.4. Macular Degeneration
11.20. Sweden Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.20.1. Retail Pharmacies
11.20.2. Online pharmacies
11.20.3. Hospital pharmacies
11.21. CIS countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.21.1. Myopic Choroidal Neovascularization
11.21.2. Macular Edema
11.21.3. Diabetic Retinopathy
11.21.4. Macular Degeneration
11.22. CIS countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.22.1. Retail Pharmacies
11.22.2. Online pharmacies
11.22.3. Hospital pharmacies
11.23. Rest of Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
11.23.1. Myopic Choroidal Neovascularization
11.23.2. Macular Edema
11.23.3. Diabetic Retinopathy
11.23.4. Macular Degeneration
11.24. Rest of Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
11.24.1. Retail Pharmacies
11.24.2. Online pharmacies
11.24.3. Hospital pharmacies
11.25. Europe Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis
11.25.1. By Distribution Channel
11.25.2. By Indication Type
11.26. PEST Analysis
11.27. Key Trends
11.28. Key Developments

12. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Analysis
12.1. Key Findings
12.2. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Overview
12.3. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type
12.4. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.4.1. Myopic Choroidal Neovascularization
12.4.2. Macular Edema
12.4.3. Diabetic Retinopathy
12.4.4. Macular Degeneration
12.5. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel
12.6. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.6.1. Retail Pharmacies
12.6.2. Online pharmacies
12.6.3. Hospital pharmacies
12.7. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country
12.8. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Analysis, By Country
12.10. China Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.10.1. Myopic Choroidal Neovascularization
12.10.2. Macular Edema
12.10.3. Diabetic Retinopathy
12.10.4. Macular Degeneration
12.11. China Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.11.1. Retail Pharmacies
12.11.2. Online pharmacies
12.11.3. Hospital pharmacies
12.12. India Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.12.1. Myopic Choroidal Neovascularization
12.12.2. Macular Edema
12.12.3. Diabetic Retinopathy
12.12.4. Macular Degeneration
12.13. India Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.13.1. Retail Pharmacies
12.13.2. Online pharmacies
12.13.3. Hospital pharmacies
12.14. Japan Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.14.1. Myopic Choroidal Neovascularization
12.14.2. Macular Edema
12.14.3. Diabetic Retinopathy
12.14.4. Macular Degeneration
12.15. Japan Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.15.1. Retail Pharmacies
12.15.2. Online pharmacies
12.15.3. Hospital pharmacies
12.16. South Korea Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.16.1. Myopic Choroidal Neovascularization
12.16.2. Macular Edema
12.16.3. Diabetic Retinopathy
12.16.4. Macular Degeneration
12.17. South Korea Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.17.1. Retail Pharmacies
12.17.2. Online pharmacies
12.17.3. Hospital pharmacies
12.18. Australia Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.18.1. Myopic Choroidal Neovascularization
12.18.2. Macular Edema
12.18.3. Diabetic Retinopathy
12.18.4. Macular Degeneration
12.19. Australia Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.19.1. Retail Pharmacies
12.19.2. Online pharmacies
12.19.3. Hospital pharmacies
12.20. ASEAN Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.20.1. Myopic Choroidal Neovascularization
12.20.2. Macular Edema
12.20.3. Diabetic Retinopathy
12.20.4. Macular Degeneration
12.21. ASEAN Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.21.1. Retail Pharmacies
12.21.2. Online pharmacies
12.21.3. Hospital pharmacies
12.22. Rest of Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
12.22.1. Myopic Choroidal Neovascularization
12.22.2. Macular Edema
12.22.3. Diabetic Retinopathy
12.22.4. Macular Degeneration
12.23. Rest of Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
12.23.1. Retail Pharmacies
12.23.2. Online pharmacies
12.23.3. Hospital pharmacies
12.24. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis
12.24.1. By Indication Type
12.24.2. By Distribution Channel
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments

13. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Overview
13.3. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type
13.4. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
13.4.1. Myopic Choroidal Neovascularization
13.4.2. Macular Edema
13.4.3. Diabetic Retinopathy
13.4.4. Macular Degeneration
13.5. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel
13.6. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
13.6.1. Retail Pharmacies
13.6.2. Online pharmacies
13.6.3. Hospital pharmacies
13.7. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country
13.8. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Country
13.8.1. GCC Countries
13.8.2. South Africa
13.8.3. Nigeria
13.8.4. Egypt
13.8.5. Rest of Middle East & Africa
13.9. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Analysis, By Country
13.10. GCC Countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
13.10.1. Myopic Choroidal Neovascularization
13.10.2. Macular Edema
13.10.3. Diabetic Retinopathy
13.10.4. Macular Degeneration
13.11. GCC Countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
13.11.1. Retail Pharmacies
13.11.2. Online pharmacies
13.11.3. Hospital pharmacies
13.12. South Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
13.12.1. Myopic Choroidal Neovascularization
13.12.2. Macular Edema
13.12.3. Diabetic Retinopathy
13.12.4. Macular Degeneration
13.13. South Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
13.13.1. Retail Pharmacies
13.13.2. Online pharmacies
13.13.3. Hospital pharmacies
13.14. Nigeria Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
13.14.1. Myopic Choroidal Neovascularization
13.14.2. Macular Edema
13.14.3. Diabetic Retinopathy
13.14.4. Macular Degeneration
13.15. Nigeria Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
13.15.1. Retail Pharmacies
13.15.2. Online pharmacies
13.15.3. Hospital pharmacies
13.16. Egypt Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
13.16.1. Myopic Choroidal Neovascularization
13.16.2. Macular Edema
13.16.3. Diabetic Retinopathy
13.16.4. Macular Degeneration
13.17. Egypt Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
13.17.1. Retail Pharmacies
13.17.2. Online pharmacies
13.17.3. Hospital pharmacies
13.18. Rest of Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
13.18.1. Myopic Choroidal Neovascularization
13.18.2. Macular Edema
13.18.3. Diabetic Retinopathy
13.18.4. Macular Degeneration
13.19. Rest of Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
13.19.1. Retail Pharmacies
13.19.2. Online pharmacies
13.19.3. Hospital pharmacies
13.20. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis
13.20.1. By Indication Type
13.20.2. By Distribution Channel
13.21. PEST Analysis
13.22. Key Trends
13.23. Key Developments

14. South America Anti-angiogenic Ophthalmic Agents Market Analysis
14.1. Key Findings
14.2. South America Anti-angiogenic Ophthalmic Agents Market Overview
14.3. South America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type
14.4. South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
14.4.1. Myopic Choroidal Neovascularization
14.4.2. Macular Edema
14.4.3. Diabetic Retinopathy
14.4.4. Macular Degeneration
14.5. South America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel
14.6. South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
14.6.1. Retail Pharmacies
14.6.2. Online pharmacies
14.6.3. Hospital pharmacies
14.7. South America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country
14.8. South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Country
14.8.1. Brazil
14.8.2. Colombia
14.8.3. Argentina
14.8.4. Rest of South America
14.9. South America Anti-angiogenic Ophthalmic Agents Market Analysis, By Country
14.10. Brazil Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
14.10.1. Myopic Choroidal Neovascularization
14.10.2. Macular Edema
14.10.3. Diabetic Retinopathy
14.10.4. Macular Degeneration
14.11. Brazil Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
14.11.1. Retail Pharmacies
14.11.2. Online pharmacies
14.11.3. Hospital pharmacies
14.12. Colombia Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
14.12.1. Myopic Choroidal Neovascularization
14.12.2. Macular Edema
14.12.3. Diabetic Retinopathy
14.12.4. Macular Degeneration
14.13. Colombia Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
14.13.1. Retail Pharmacies
14.13.2. Online pharmacies
14.13.3. Hospital pharmacies
14.14. Argentina Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
14.14.1. Myopic Choroidal Neovascularization
14.14.2. Macular Edema
14.14.3. Diabetic Retinopathy
14.14.4. Macular Degeneration
14.15. Argentina Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
14.15.1. Retail Pharmacies
14.15.2. Online pharmacies
14.15.3. Hospital pharmacies
14.16. Rest of South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type
14.16.1. Myopic Choroidal Neovascularization
14.16.2. Macular Edema
14.16.3. Diabetic Retinopathy
14.16.4. Macular Degeneration
14.17. Rest of South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel
14.17.1. Retail Pharmacies
14.17.2. Online pharmacies
14.17.3. Hospital pharmacies
14.18. South America Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis
14.18.1. By Indication Type
14.18.2. By Distribution Channel
14.19. PEST Analysis
14.20. Key Trends
14.21. Key Developments

15. Company Profiles
15.1. Market Share Analysis, By Company
15.2. Competition Matrix

15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A By Regions, Investment and Component
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration

15.3. Company Profiles: Key Players
15.3.1. Gilead Sciences, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. Eyetech Inc.
15.3.3. Becton, Dickinson and Company
15.3.4. Regeneron Pharmaceuticals, Inc.
15.3.5. Genentech, Inc.
15.3.6. Novartis AG
15.3.7. Allergan plc
15.3.8. Bayer AG
15.3.9. Santen Pharmaceutical Co., Ltd.
15.3.10. Shanghai Pharmaceuticals
15.3.11. Johnson & Johnson
15.3.12. Pfizer
15.3.13. Sun Pharma
15.3.14. Otsuka Pharmaceutical Co. Ltd
15.3.15. Daiichi Sankyo
15.3.16. ERC Labs
15.3.17. Medicom Health care
15.3.18. Implandata ophthalmic products GmbH
15.3.19. The Geuder Group, MORCHER GmbH
15.3.20. Novamedika

16. Primary key Insights
  • INQUIRE BEFORE BUYING